Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962505 | 0.90 | MAOA (0.84) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL21114365 | 0.83 | CYP1A2 (1.00) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL75140 | 0.83 | CYP1A2 (1.00) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL29829339 | 0.83 | CYP1A2 (1.00) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL29364009 | 0.83 | CYP1A2 (1.00) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| SCHEMBL3345432 | 0.81 | CYP1A2 (0.70) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL6903872 | 0.81 | CYP1A2 (0.97) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| 2-Acetylaminofluorene SCHEMBL5663545 | 0.78 | CYP1A2 (0.89) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| SCHEMBL9236650 | 0.77 | RAB9A (0.56) | MAOACYP1A2ADRA2ASLC6A2HTR2C | |
| SCHEMBL28178463 | 0.76 | CYP1A2 (0.88) | MAOACYP1A2ADRA2ASLC6A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0158758-A1 | Probe containing a modified nucleic acid recognizable by specific antibodies and the use to detect and characterize a homologous DNA sequence | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1985-10-23 | — | — | EP | claimed |
| EP-1245286-B1 | Reaction tube and method of use to minimize contamination | ABBOTT LAB (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1309563-B1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | AGOURON PHARMA (US) | 2005-05-11 | — | — | EP | disclosed |
| EP-1309563-A1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | Agouron Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1262560-A2 | Method of forming cDNA from an RNA target sequence present in a sample | Abbott Laboratories (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6462060-B2 | MEDIATING TYROSINE KINASE SIGNAL TRANSDUCTION; TREATING TUMOR GROWTH, CELL PROLIFERATION, OR ANGIOGENESIS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1245286-A2 | Reaction tube and method of use to minimize contamination | Abbott Laboratories (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-0695367-A4 | LIGASE CHAIN REACTION WITH ENDONUCLEASE IV CORRECTION AND CONTAMINATION CONTROL | ABBOTT LAB (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020049238-A1 | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CHONG WESLEY KWON MUNG (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2002016326-A1 | HETEROCYCLIC-HYDROXYIMINO-FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0695367-A1 | LIGASE CHAIN REACTION WITH ENDONUCLEASE IV CORRECTION AND CONTAMINATION CONTROL | ABBOTT LABORATORIES (US) | 1996-02-07 | — | — | EP | disclosed |
| WO-1995011083-A2 | REACTION TUBE AND METHOD OF USE TO MINIMIZE CONTAMINATION | ABBOTT LABORATORIES (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0642592-A1 | LIGASE CHAIN REACTION STARTING WITH RNA SEQUENCES | ABBOTT LABORATORIES (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1995006756-A2 | OLIGONUCLEOTIDES AND METHODS FOR THE DETECTION OF $i(CHLAMYDIA TRACHOMATIS) | ABBOTT LABORATORIES (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1995002690-A1 | NUCLEOTIDE SEQUENCES AND PROCESS FOR AMPLIFYING AND DETECTION OF HEPATITIS B VIRUS | ABBOTT LABORATORIES (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0633944-A1 | METHOD OF MULTIPLEX LIGASE CHAIN REACTION | ABBOTT LABORATORIES (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1994024311-A1 | LIGASE CHAIN REACTION WITH ENDONUCLEASE IV CORRECTION AND CONTAMINATION CONTROL | ABBOTT LABORATORIES (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1993024656-A1 | LIGASE CHAIN REACTION STARTING WITH RNA SEQUENCES | ABBOTT LABORATORIES (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993020227-A1 | METHOD OF MULTIPLEX LIGASE CHAIN REACTION | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993020240-A1 | METHOD AND DEVICE FOR DETECTION OF NUCLEIC ACID OR ANALYTE USING TOTAL INTERNAL REFLECTANCE | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049238-A1 | Heterocyclic-hydroxyimino-fluorene nuclei compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CHUK, BRAF, UACA | MAOA 2297/4885CYP1A2 3444/4885ADRA2A 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.